Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Thyroid Cancer, Papillary 1Solid Cancers 1Obesity 1Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

pembrolizumab 47Nivolumab 34Sunitinib 18Cyclophosphamide 18Everolimus 17Ipilimumab 15cabozantinib 14pazopanib 13Bevacizumab 13fludarabine 12atezolizumab 11temsirolimus 10Magnetic Resonance Spectroscopy 10Sorafenib 9aldesleukin 8Specimen Handling 8Paclitaxel 8Sirolimus 7CTLA-4 Antigen 7Axitinib 7belzutifan 6Radiosurgery 6Oxaliplatin 6Interleukin-2 6Fluorouracil 6spartalizumab 5avelumab 5Leucovorin 5Irinotecan 5Docetaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Renal Cell × Rosiglitazone × Clear all
NCT01100619 2013-09-19

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Exelixis

Phase 1 Completed
40 enrolled
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Carcinoma, Renal Cell, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡